PHYOX™ Clinical Trial Program

Dicerna’s lead GalXC™ product candidate, nedosiran, formerly known as DCR-PHXC, is in clinical development for the treatment of known forms of primary hyperoxaluria (PH) – PH1, PH2, and PH3. The PHYOX7, PHYOX8, and PHYOX-OBX trials are now enrolling patients. Please find further details on these studies below.

PHYOX™ Clinical Trial Program

Dicerna’s lead GalXC™ product candidate, nedosiran, formerly known as DCR-PHXC, is in clinical development for the treatment of known forms of primary hyperoxaluria (PH) – PH1, PH2, and PH3. The PHYOX7, PHYOX8, and PHYOX-OBX trials are now enrolling patients. Please find further details on these studies below.

PHYOX™ Clinical Trial Program

Dicerna’s lead GalXC™ product candidate, nedosiran, formerly known as DCR-PHXC, is in clinical development for the treatment of known forms of primary hyperoxaluria (PH) – PH1, PH2, and PH3. The PHYOX7, PHYOX8, and PHYOX-OBX trials are now enrolling patients. Please find further details on these studies below.

Participating in a Trial

Physicians at leading research institutions who specialize in the treatment of PH are conducting the PHYOX™ clinical trials.

If you or a loved one has been diagnosed with PH and would like to participate in a clinical trial, please submit your information through the forms on the appropriate study pages. Please note, depending on a person’s eligibility to participate in the clinical trial, travel expenses to a clinical trial site will be covered by Dicerna.

Enrolling Studies

for participants with PH1 or PH2 and severe renal impairment, with or without dialysis

(NCT04580420)

This website is not live yet, please check back soon!

for PH patients aged 0-11 years with relatively intact renal function

(NCT05001269)

This website is not live yet, please check back soon!

for participants with PH3 who have a history of stone events

(NCT04542590)

Observational study

This website is not live yet, please check back soon!

Studies Closed to Recruitment

for participants with PH1 or PH2

(NCT03847909)

ENROLLMENT CLOSED

Dicerna’s pivotal trial was designed to evaluate the efficacy and safety of nedosiran delivered as a once-monthly subcutaneous injection in participants aged six years and older who have PH1 or PH2. Enrollment of 35 participants was completed in December 2020 and included participants across 11 countries, including the U.S., Japan and Europe

for participants who complete PHYOX™ trials

(NCT04042402)

INVITATION ONLY

Dicerna’s ongoing open-label four-year extension study for participants who have completed another PHYOX™ study (except PHYOX7)

Siblings of participants in this trial may be enrolled directly into PHYOX3, if eligible

for participants with PH3

(NCT04555486)

ENROLLMENT CLOSED

Dicerna’s PHYOX4 trial was designed as a single-dose open-label study in participants aged six years and older diagnosed with PH3

For more information about the PHYOX™ clinical trial program or to find participating clinical trial sites, please contact Dicerna at medicalinfo@dicerna.com or go to https://www.clinicaltrials.gov/ and search for the respective NCT identifier number listed above.

Residents of the European Union can use EudraCT, a database of ongoing clinical trials in the EU, to access more information about the PHYOX™ trials.